NEW YORK (360Dx) – I-Med Pharma announced this week it has won a patent case in Canada against TearLab related to the I-Pen Osmolarity System.

In February 2016, TearLab filed suit in the Federal Court of Canada alleging that I-Med Pharma's I-Pen infringed on the Canadian patent for the TearLab Osmolarity System. TearLab sought a permanent injunction to keep the I-Pen off the market, as well as damages, according to I-Med Pharma.

This week, the court invalidated TearLab's patent claims and awarded costs to I-Med Pharma. TearLab said it plans to appeal the ruling.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.